Clinical trials: Solid Tumors, completed
Hormone Receptor-Positive Breast, Gynecologic
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Background: Some types of cancer cells that have hormone receptors on their surfaces need the hormone estrogen to grow. The drug tamoxifen blocks estrogen from binding to the tumor cells, which helps to slow or stop the growth of…
- Conditions
- Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms
- Trial name
- NCT01273168
- Testing
- Z-Endoxifen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumors, Adult
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with advanced solid tumor will be enrolled.
- Trial name
- NCT04587479
- Testing
- JAB-8263
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Solid Tumor
Bioequivalence Study of Famitinib Malate in Healthy Volunteers Under Fasting Condition
The study is a single-centre, randomized, open, 2-period, 2-sequence crossover design clinical trial. It is planned to enroll 28 healthy subjects. Subjects will receive famitinib malate on Day1 and Day13.
- Trial name
- NCT05336279
- Testing
- famitinib malate T(5 mg*4)、famitinib malate R(20 mg)
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer
Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with carboplatin and/or Paclitaxel chemotherapy.
- Conditions
- Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin, Paclitaxel
- Trial name
- NCT00516724
- Testing
- KU-0059436 (AZD2281)(PARP inhibitor), Carboplatin, Paclitaxel
- Where
- 4 sites in Belgium, Netherlands and 1 more
- Volunteers
- 189 people
- Sponsor
- AstraZeneca
Advanced or Metastatic Solid Tumors
A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors.
- Trial name
- FLAGSHP-1 (NCT04670679)
- Testing
- ERAS-601, Cetuximab, Pembrolizumab
- Where
- 14 sites in United States, Australia
- Volunteers
- 90 people
- Sponsor
- Erasca, Inc.
Advanced Lung Cancer, Ovarian Cancer
Clinical Study of AL2846 Capsules in the Treatment of Advanced Lung Tumor and Advanced Ovarian Cancer
This is a multi-cohort, randomized, open, multicenter Phase II study to evaluate the efficacy and safety of AL2846 capsules in patients with advanced lung cancer and ovarian cancer.
- Trial name
- NCT05815862
- Testing
- AL2846 capsule
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Refractory Solid Tumors, Leukemia
Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia
Phase I Study of Bevacizumab and Sorafenib Combined with Low Dose Cyclophosphamide in Patients with Refractory Solid Tumors and Leukemia.
- Trial name
- NCT00665990
- Testing
- Bevacizumab, Sorafenib, Cyclophosphamide
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- St. Jude Children's Research Hospital
Advanced Solid Tumor
An Phase I Study of YY001 in Patients with Advanced Solid Tumors
The safety and tolerability of YY001 in the treatment of patients with advanced solid tumors were evaluated, and the possible dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) or recommended phase II clinical dose…
- Trial name
- NCT06228846
- Testing
- YY001
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Shanghai Yuyao Biotech Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004090
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Sponsor
- Northwestern University
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Drugs to Reduce the Side Effects of Chemotherapy
RATIONALE: Antiemetic drugs may help to reduce or prevent nausea and vomiting in patients treated with chemotherapy. It is not known whether receiving dexamethasone with granisetron is more effective than receiving dexamethasone…
- Trial name
- NCT00003213
- Testing
- dexamethasone, granisetron hydrochloride, metoclopramide hydrochloride
- Where
- 10 sites in Italy, Switzerland
- Volunteers
- 267 people
- Sponsor
- Swiss Cancer Institute
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum…
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
- Trial name
- NCT00421889
- Testing
- belinostat, Paclitaxel, Carboplatin
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 80 people
- Sponsor
- Valerio Therapeutics
Cancer (Solid Tumors), Cancer and / or Hematological Malignancy
Comparative Effectiveness of Verbal Instruction Versus Simulation Video Education Among Cancer Patients Undergoing Radiation Therapy
The goal of this Randomized Controlled Trial is to compare the effectiveness of radiotherapy-specific, physician-led educational videos introduced before the initial Radiation Therapy consultation .
- Trial name
- CARE-RT (NCT07367997)
- Testing
- Radiotherapy-Specific Educational Video
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Advanced Solid Tumors, Lymphoma
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance.
- Conditions
- Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT03841110
- Testing
- FT500, Nivolumab, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fate Therapeutics
Advanced Solid Malignancies
A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies
This is a phase I trial to determine the maximum tolerated dose and recommended phase II dose of docetaxel-PNP (polymeric nanoparticle formulation of docetaxel) and to evaluate the safety and pharmacokinetics of docetaxel-PNP in…
- Trial name
- NCT01103791
- Testing
- Docetaxel-PNP
- Where
- South Korea
- Volunteers
- 19 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Breast Carcinoma, Digestive System Neoplasm
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
This phase I trial collects blood samples to investigate the prevalence of changes in genes (genetic mutations) in solid tumor patient populations seeking care at Mayo Clinic Embedded Cancer Center at St. Vincent's Riverside.
- Conditions
- Breast Carcinoma, Digestive System Neoplasm, Malignant Brain Neoplasm, Malignant Central Nervous System Neoplasm
- Trial name
- NCT04456140
- Testing
- Biospecimen Collection, Genetic Counseling, Genetic Testing
- Where
- 2 sites in United States
- Volunteers
- 230 people
- Sponsor
- Mayo Clinic
Solid Tumors
A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Linifanib (ABT-869)
This is a phase 1, open-label study designed to determine the interaction of ketoconazole with ABT-869.
- Trial name
- NCT01114191
- Testing
- ABT-869, ketoconazole
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Abbott
Advanced Solid Tumors, Metastatic Colorectal Cancer
BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
The purpose of this study is to establish the safety and tolerability of BKM120 when combined with mFOLFOX6 and to define the maximum tolerated dose of BKM120 in this combination in advanced solid tumors including metastatic…
- Conditions
- Advanced Solid Tumors, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer
- Trial name
- NCT01571024
- Testing
- BKM120, mFOLFOX6
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Solid Tumor
LZM009 to Treat Patients With Advanced Solid Tumors
To assess the safety and tolerability of IV administered LZM009 in subjects with advanced solid tumors who have progressed or are non-responsive to available therapies.
- Trial name
- NCT03286296
- Testing
- LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -
Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours
First time in patients study of AZD8835. The study has four parts. Part A AZD8835 is administered as a single agent in a multiple ascending dose escalation phase to investigate dose level for monotherapy.
- Conditions
- Advanced Solid Malignancies, Breast Cancer - ER+, HER2 -, Breast Cancer - ER+, HER2-, PIK3CA Gene Mutation
- Trial name
- NCT02260661
- Testing
- AZD8835, AZD8835 in combination with fulvestrant
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 20 people
- Sponsor
- AstraZeneca
Advanced or Metastatic Solid Malignancies
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies
- Trial name
- NCT04887870
- Testing
- Sitravatinib, Nivolumab, Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 49 people
- Sponsor
- Mirati Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.